Citi initiated coverage of Ionis Pharmaceuticals (IONS) with a Buy rating and $115 price target and named it a top pick among small-to-mid cap biotech stocks. Tryngloza for severe hypertriglyceridemia leads the higher value proprietary pipeline, with a greater than $3.5B peak sales opportunity “underappreciated,” the analyst tells investors. Partnered Phase 3 readouts offer opportunities for upside momentum in the second half of 2026, the analyst added.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals: Buy Rating Reaffirmed as Alzheimer’s Program Advances and Price Target Raised to $111 from $100
- Pelacarsen Phase 3 HORIZON Trial Seen as Key Catalyst Supporting Ionis Buy Rating and Unchanged $105 Price Target
- Ionis Pharmaceuticals participates in a conference call with Cantor
- Biogen’s diranersen shows benefits in early Alzheimer’s Disease
- Ionis announces Biogen’s CELIA study did not meet primary endpoint